Enzo Biochem’s Clinical Labs Subsidiary Launches Drive-Through Facility to Provide COVID-19 Testing on Long Island
March 24 2020 - 7:30AM
Business Wire
Company Ramping up Availability and Access
to Testing
Enzo Biochem, Inc. (NYSE:ENZ), a leading biotechnology and
diagnostic company, today announced its wholly owned subsidiary,
Enzo Clinical Labs, Inc., has expanded its screening services for
COVID-19. Following the company’s March 6, 2020 announcement
regarding the initiation of accepting specimens for novel
Coronavirus (COVID-19) testing, Enzo is now directly collecting
specimens at a drive-through facility by appointment in Enzo’s
laboratory complex in Farmingdale, New York. This facility has been
set up with support from local and state officials.
As one of the first independent drive-through testing facilities
on Long Island, NY, it is easily accessible for Nassau and Suffolk
County residents and is now in operation. The goal of this testing
site is to help the local community improve virus surveillance and
reduce pressure on the regional hospital systems.
Enzo President Barry Weiner commented: “Enzo understands and
takes seriously its responsibility as a leading and resourceful
diagnostic and clinical laboratory to help alleviate the present
bottleneck existing around COVID-19 testing in the communities we
serve during this rapidly evolving pandemic environment. We are
partnering with State and Local officials to bring access and
availability to the nearly eight million people in the underserved
Long Island, New York, communities. Our technical staff is
committed to do what it takes in providing necessary patient care.
We appreciate the government and public support that has enabled
Enzo to quickly establish this facility and continue to serve the
Long Island community with the highest standards. We also are
exploring how we can apply our many years of technical know-how and
manufacturing experience to contribute to testing
alternatives.”
To receive testing, patients who are concerned that they or a
family member are exhibiting symptoms of COVID-19 must initially
consult a physician. If directed by the physician, the patient will
receive a prescription (“script”) with which the patient can make
an appointment by phone for COVID-19 testing at the Farmingdale
facility. Once the patient arrives at the scheduled time for the
appointment, he/she will remain in their car and must present a
photo-ID for verification as well as any other necessary
documentation. A healthcare professional with protective gear will
collect a sample using a nasal swab (similar to a flu test). The
specimen will be sent to Enzo’s clinical laboratory facility for
processing, and test results will be available in a timely manner
through the ordering physician or, by request, directly to the
patients.
Further information is available on Enzo’s website at:
http://www.enzoclinicallabs.com/coronavirus
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and
intellectual property through the development of unique diagnostic
platform technologies that provide numerous advantages over
previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products, systems and
services that meet the ever-changing and rapidly growing needs of
health care today and into the future. Underpinning Enzo Biochem’s
products and technologies is a broad and deep intellectual property
portfolio, with patent coverage across a number of key enabling
technologies.
Forward-Looking
Statements
Except for historical information, the matters discussed in this
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
Such statements include declarations regarding the intent, belief
or current expectations of the Company and its management,
including those related to cash flow, gross margins, revenues, and
expenses which are dependent on a number of factors outside of the
control of the Company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other
expenses, government regulations, litigation, and general business
conditions. See Risk Factors in the Company’s Form 10-K for the
fiscal year ended July 31, 2019. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that
could materially affect actual results. The Company disclaims any
obligations to update any forward-looking statement as a result of
developments occurring after the date of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200324005130/en/
Enzo Biochem, Inc. David Bench, CFO 212-583-0100 dbench@enzo.com
Steve Anreder Anreder & Company 212-532-3232
Steven.anreder@anreder.com Elliot Sloane ESPR LLC 917-291-0833
Elliot.espr@gmail.com
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2023 to Apr 2024